论文部分内容阅读
目的:本文主要针对受体阳性晚期乳腺癌患者采取氟维司群进行治疗的临床效果进行探讨研究.方法:本课题研究主要的研究样本是选择近1年来我院进行治疗的受体阳性晚期乳腺癌患者,样本量抽取90例,然后将这些样本量分两组,其中一个组设定成常规组,该组中的受体阳性晚期乳腺癌患者(45例)采取低剂量氟维司群进行治疗,另外一个组则设定为研究组,该组中的受体阳性晚期乳腺癌患者(45例)采取高剂量氟维司群实施治疗;样本分组完成之后,对两组患者的发生不良反应率、治疗效果以及治疗满意度进行统计评估.结果:针对实验研究期间所得数据进行“,”Objective This paper mainly aimed to investigate the clinical effect of fulvestrant treatment in patients with receptor positive advanced breast cancer. Methods: the main research sample of this subject study was to select receptor positive advanced breast cancer patients who were treated in our hospital for nearly 1 year, and the sample size was 90 cases, and then these sample sizes were divided into two groups, one of which was set into a routine group, and the receptor positive advanced breast cancer patients in this group (45 cases) were treated with low-dose fulvestrant, An additional group was set up as the study group, in which patients with receptor positive advanced breast cancer (45 cases) were managed with high-dose fulvestrant implementation; After completion of sample grouping, the incidence of adverse effects, treatment efficacy as well as treatment satisfaction were statistically assessed for both groups. Results: in view of the data obtained during the experimental study, we can master that after a period of treatment, the probability analysis of the occurrence of adverse effects in the two groups, the probability of the study group is 20.00％, the conventional group is 37.78％, and the probability of the former is lower (P ＜ 0.05); The overall response rate of 95.55％ to treatment in the study group was significantly higher (P ＜ 0.05) than the overall response rate of 82.21％ in the conventional group. Analyzing the satisfaction with treatment between groups, the total satisfaction of the study group was 95.56％ compared with 75.56％ in the conventional group, which was significantly higher in the study group (P ＜ 0.05; Conclusions: This study concluded by adopting high-dose fulvestrant treatment for patients with receptor positive advanced breast cancer, this care model may reduce the probability of patients developing adverse effects, improve patient satisfaction with treatment and treatment efficacy, and has clinical application value, while also has a certain guiding role for follow-up studies.